Inactive Instrument

News Flexion Therapeutics, Inc.

Equities

FLXN

US33938J1060

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

Renovacor Names New CFO	22-03-28	MT
Pacira BioSciences Logs Higher Exparel, Iovera Sales in November	21-12-07	MT
North American Morning Briefing : Stock Futures -3-	21-11-22	DJ
Northland Securities Downgrades Flexion Therapeutics to Market Perform From Outperform, Price Target $10	21-11-19	MT
FLEXION THERAPEUTICS INC : Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control or Registrant, (form 8-K)	21-11-19	AQ
Flexion Therapeutics, Inc.(NasdaqGM:FLXN) dropped from NASDAQ Composite Index	21-11-19	CI
Flexion Therapeutics, Inc.(NasdaqGM:FLXN) dropped from S&P Global BMI Index	21-11-19	CI
Flexion Therapeutics, Inc.(NasdaqGM:FLXN) dropped from S&P TMI Index	21-11-19	CI
Pacira BioSciences, Inc. completed the acquisition of Flexion Therapeutics, Inc..	21-11-18	CI
Flexion Therapeutics, Inc.(NasdaqGM:FLXN) dropped from NASDAQ Biotechnology Index	21-11-18	CI
FLEXION THERAPEUTICS INC MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q)	21-11-12	AQ
Flexion Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	21-11-12	CI
North American Morning Briefing : Stock Futures -3-	21-10-20	DJ
FLEXION THERAPEUTICS : HC Wainwright Downgrades Flexion Therapeutics to Neutral From Buy, Price Target at $10	21-10-19	MT
North American Morning Briefing : Stock Futures -3-	21-10-13	DJ
FLEXION THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Flexion Therapeutics, Inc. - FLXN	21-10-12	BU
FLEXION THERAPEUTICS : BMO Capital Downgrades Flexion Therapeutics to Market Perform Rating From Outperform, Adjusts Price Target to $12 From $20	21-10-12	MT
FLEXION THERAPEUTICS : Credit Suisse Downgrades Flexion Therapeutics to Neutral from Outperform Following News of Sale to Pacira BioSciences, Lowers PT to $10 from $14	21-10-12	MT
FLEXION THERAPEUTICS : Credit Suisse Downgrades Flexion Therapeutics to Neutral From Outperform, Cuts Price Target to $10 From $14	21-10-12	MT
FLEXION THERAPEUTICS : Raymond James Downgrades Flexion Therapeutics to Market Perform From Strong Buy	21-10-12	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Flexion Therapeutics, Inc.

Equities

FLXN

US33938J1060

Summary

Filters